Klein AD, Mazzulli JR. Is Parkinson’s disease a lysosomal disorder? Brain 2018, In Press. doi: 10.1093/brain/awy147 Calderon JF, Klein AD. Controversies on the potential therapeutic use of rapamycin for treating a lysosomal cholesterol storage disease . Mol Gen and Metabol Rep, 2018; 15:135-136 Klein AD, Modeling diseases in multiple mouse strains for precision medicine studies . Physiol Genomics 2017, 49(3):177-179. Klein AD, Ferreira NS, Ben-Dor S, Duan J, Merrill Jr AH, Hardy J, Cox T, Futerman AH. Identification of modifier genes in a mouse model of Gaucher disease . Cell Rep 2016; 6(10):2546-53. Klein AD, Alvarez AR, Zanlungo S. The unique case of the Niemann-Pick type C cholesterol storage disorder . Pediatr Endocrinol Rev. 2014;12 Suppl 1:166-75 Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD, Platt FM, Cox TM, Futerman AH. RIP3 as a novel therapeutic target for Gaucher disease. Nat Med. 2014; 20(2):204-8. Klein AD, Futerman AH. Lysosomal Storage Disorders: Old diseases, present and future challenges . Pediatr Endocrinol Rev. 2013; Suppl 1:59-63. Parra J*, Klein A*, Castro J, Morales MG, Mosqueira M, Valencia I, Cortés V, Rigotti A, Zanlungo S. Npc1 deficiency in C57BL/6J genetic background enhances Niemann-Pick type C spleen pathology . *both as first authors. Biochem Biophys Res Commun. 2011; 413(3):400-6. Alvarez AR*, Klein A*, Castro J, Cancino GI, Amigo J, Mosqueira M, Vargas LM, Yevenes FL, Bronfman FC, Zanlungo S (2008). Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann Pick type C disease . Faseb Journal 22(10):3617-27. *both as first authors. Klein A, Amigo L, Retamal MJ, Morales MG, Miquel JF, Rigotti A, Zanlungo S (2006). NPC2 is expressed in human and murine liver and secreted into bile: potential implications for body cholesterol homeostasis . Hepatology., 43:126-33.
